Eric Quéméneur

Deputy Chief Executive Officer, Director-Research & Development at Transgene SA

Eric Quéméneur

Eric Quéméneur

Deputy Chief Executive Officer, Director-Research & Development at Transgene SA

Biography

Eric Quéméneur joined Transgene in September 2014 as Executive Vice President in charge of Research and Development. Before joining Transgene, he spent over 20 years at the CEA (Atomic Energy Commission) where he was Director of research programs and industrial partnerships in the life science division. His responsibilities included: the management of R&D programs and their transition into applications, the management of multidisciplinary teams and the development of national and international alliances. Eric Quéméneur has a PhD in Biochemistry from the Claude Bernard University in Lyon, France. He is the author of nearly 80 articles published in international scientific journals.

Overview
Career Highlights

Transgene SA

RelSci Relationships

102

Number of Boards

3

Birthday

1964

Age

57

Relationships
RelSci Relationships are individuals Eric Quéméneur likely has professional access to. A relationship does not necessarily indicate a personal connection.

Chief Executive Officer, Co-Founder at Elsalys Biotech SAS

Relationship likelihood: Strong

Chief Executive Officer at TSGH SAS

Relationship likelihood: Strong

Chief Executive Officer at SparingVision SAS

Relationship likelihood: Strong

Vice President-Responsible Pharmacist, Quality & Deputy Chief Executive Officer, Member of the Management Committee at Transgene SA

Relationship likelihood: Strong

Chairman & Chief Executive Officer at Transgene SA

Relationship likelihood: Strong

Vice Chairman at Association Lyon Place Financière

Relationship likelihood: Strong

Vice President, Corporate Secretary & General Counsel at Transgene SA

Relationship likelihood: Strong

Vice President, Finance at Transgene SA

Relationship likelihood: Strong

Former Director-Quality Assurance & Compliance at Transgene SA

Relationship likelihood: Strong

Vice President, Alliance Management, Project Management & Marketing at Transgene SA

Relationship likelihood: Strong

Paths to Eric Quéméneur
Potential Connections via
Relationship Science
You
Eric Quéméneur
Deputy Chief Executive Officer, Director-Research & Development at Transgene SA
Education
Class of 1986

INSA Lyon applies a policy of excellence implemented at all levels.

The Université Claude Bernard Lyon 1, also known as Université Lyon 1 or UCBL, is one of the three public universities of Lyon, France. The dominant areas of study covered by the university are science and medicine. The main administrative, teaching and research facilities are located in Villeurbanne. Other campus are the domains of Gerland, Rockefeller and Laennec. Attached to the University are the "Hospices civils de Lyon" including the "Centre hospitalier Lyon Sud", which is the largest teaching hospital in the Rhône-Alpes region and second largest in France.

Career History
Deputy Chief Executive Officer, Director-Research & Development
2014 - Current

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4001, TG6002, BT-001 and TG4050. The company was founded in December 1979 and is headquartered in Strasbourg, France.

Executive Vice President, Research & Development
Prior

ElsaLys Biotech SAS provides therapeutic monoclonal antibody player services. It involves in cellular events at the core of the pathological process: immune response, angiogenesis, survival, proliferation, adhesion and migration. The company also designs and develops a new generation of antibodies that target tumors and their immune microenvironment. ElsaLys Biotech was founded by Christine Guillen, Thierry Menguy, Vanessa Duong, and Martine Brandt in 2013 and is headquartered in Lyon, France.

Boards & Committees
Member, Management Committee
2014 - Current

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. Its products include TG4001, TG6002, BT-001 and TG4050. The company was founded in December 1979 and is headquartered in Strasbourg, France.

Member, Scientific Advisory Council
Current

Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada.

Other Affiliations

Eric Quéméneur is affiliated with Transgene SA, Elsalys Biotech SAS, Transgene SA, Medicago, Inc.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eric Quéméneur. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eric Quéméneur's profile does not indicate a business or promotional relationship of any kind between RelSci and Eric Quéméneur.